C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024

Core Insights - C4 Therapeutics, Inc. announced the release of an abstract detailing clinical data from its Phase 1 trial of CFT1946, a novel BiDAC™ degrader targeting mutant BRAF V600 solid tumors, coinciding with the ESMO Congress 2024 [1][2] - The full abstract includes results with a data cut-off of April 12, 2024, and will be presented at the ESMO Congress on September 13, 2024 [1][2] Group 1 - The Phase 1 trial data will include information on 36 patients, focusing on demographics, safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity as per RECIST 1.1 criteria [2] - The oral presentation is scheduled for September 13, 2024, at 4:10 pm CEST (10:10 am ET) during the proffered paper session [3] - C4 Therapeutics will host a webcast for analysts and investors on the same day at 12:00 pm ET, with a replay available afterward [3] Group 2 - C4 Therapeutics is a clinical-stage biopharmaceutical company focused on targeted protein degradation to develop new medicines [4] - The company's TORPEDO® platform is utilized to design and optimize small-molecule medicines for challenging diseases [4] - CFT1946 is designed to be potent and selective against BRAF V600X mutant targets, showing activity in preclinical studies against BRAF V600E driven diseases and resistant models [5] Group 3 - CFT1946 is currently undergoing a Phase 1 dose escalation study in various BRAF V600X mutant solid tumors, including colorectal cancer, melanoma, and non-small cell lung cancer [5]